Drug-drug interation prediction between ketoconazole and anti-liver cancer drug gomisin G

African Health Sciences

Volumn 15, Issue 2, 2015, Pages 590-593

  Liu, Xiaoyang ^a   Ni, Chenming ^a   Li, Chengqing ^b   Liu, Tao ^c  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b Department of General Surgery No 1 Hospital of People s Liberation Army   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CYP3A4; Gomisin G; Molecular docking

Indexed keywords

CYTOCHROME P450 3A4; GOMISIN; KETOCONAZOLE; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOOCTANE DERIVATIVE; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; LIGNAN; PLANT EXTRACT; SCHIZANDRER A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER PREDICTION; COMPUTER PROGRAM; CRYSTAL STRUCTURE; DRUG INTERACTION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY CENTER; ENZYME STRUCTURE; ENZYME SUBSTRATE; MOLECULAR DOCKING; CHEMISTRY; DRUG EFFECTS; HUMAN; LIVER; LIVER NEOPLASMS; METABOLISM; SCHISANDRA;

ANTINEOPLASTIC AGENTS; CYCLOOCTANES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DIOXOLES; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; LIGNANS; LIVER; LIVER NEOPLASMS; MOLECULAR DOCKING SIMULATION; PLANT EXTRACTS; SCHISANDRA;

EID: 84930066706     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: 10.4314/ahs.v15i2.35     Document Type: Article

References (11)

1. Szabo G, Saha B, Bukong TN. Alcohol and HCV: Implications for Liver Cancer. Adv. Exp. Med. Biol. 2015; 815: 197-216.
2. Gnabre J, Unlu I, Chang TC, Lisseck P, Bourne B, Scolnik R, Jacobsen NE, Bates R, Huang RC. Isolation of lignans from Schisandra chinensis with anti-proliferative activity in human colorectal carcinoma: structure-activity relationships. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878(28): 2693-2700.
3. Qu HM, Liu SJ, Zhang CY. Antitumor and antiangiogenic activity of Schisandra chinensis polysaccharide in a renal cell carcinoma model. Int J Biol Macromol 2014;
4. Cao YF, Zhang YY, Li J, Ge GB, Hu D, Liu HX, Huang T, Wang YC, Fang ZZ, Sun DX, Huo H, Yin J, Yang L. CYP3A catalyses schizandrin biotransformation in human, minipig, and rat liver microsomes. Xenobiotica 2010; 40(1): 38-47.
5. Jiang F, Jiang AF, Zhang LG, Li YZ, Yu SE. Molecular docking to predict the metabolic site of corynoline and the possible drug-drug interaction. Lat Am J Pharm 2013; 32(10): 1581-1583.
6. Jiang J, Liu L, Wang W, Dong N, Fu X, Pang C, Yang H, Lv J, Ding L, Sun X. Metabolic behavior prediction of anti-glioma drug gefitinib by molecular docking. Lat Am J Pharm 2014; 33(7): 1213-1215.
7. Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 2010; 69(2): 193-199.
8. Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ. Metabolic map and bioactivation of the anti-tumor drug noscapine. Br J Pharmacol 2012; 167(6): 1271-1286.
9. Fang ZZ, Gonzalez FJ. LC-MS-based metabolomics: an update. Arch Toxicol 2014; 88(8): 1491-1502.
10. Kobayashi K, Takahashi O, Hiratsuka M, Yamaotsu N, Hirono S, Watanabe Y, Oda A. Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation. PLoS One 2014; 9(5): e96789.
11. Liu T, Qian G, Wang W, Zhang Y. Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet 2014; doi: 10.1007/s13318-014-0201-1.